Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q3 2023 · 10-Q
Revenue$429.00K$429.00K+540.3% vs Q3 2022 Net Income-$6.49M-$6.49MN/M vs Q3 2022 EPS Diluted-$0.81-$0.81N/M vs Q3 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,769,000N/M Margins · derivedGross margin57.8%+459.3 pt vs Q3 2022
Operating margin-1518.2%+1028.1 pt vs Q3 2022
Net margin-1512.6%+12417.3 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end